Registry for understanding cardiovascular issues in Fabry Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The RICMAF Study is an observational, multicenter initiative in Italy aimed at improving the understanding of Anderson-Fabry Disease (AFD), particularly its cardiac manifestations. By collecting data from a nationwide patient registry, the study seeks to analyze the clinical profile, prevalence, and incidence of AFD, as well as identify early markers of cardiac involvement and predictors of cardiovascular complications. The study also aims to explore the relationship between genetic mutations and clinical presentation to enhance personalized care for patients. This comprehensive approach is designed to improve patient outcomes through better understanding and management of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with Anderson Fabry disease
* Age ≥ 2 years at diagnosis
* Obtaining informed consent from the patient and parent or legal guardian.

Exclusion Criteria:

\- None

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, EmiliaRomagna/Bologna, Italy Recruiting
• ASST Papa Giovanni XXIII
  Bergamo, Lombardia/Bergamo, Italy Recruiting
• Centro Cardiologico Monzino
  Milan, Lombardia/Milano, Italy Recruiting
• A O Universitaria Ospedali Riuniti Ancona
  Ancona, Marche/Ancona, Italy Recruiting
• AO Dei Colli - Ospedale Monaldi
  Naples, Napoli, Italy Recruiting
• Molinette
  Torino, Piemonte/Torino, Italy Recruiting

+4 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Elena Biagini, MD, PhD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Elena Biagini, MD, PhD
• Email: elena.biagini@aosp.bo.it
• Phone: +39051214483

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lucerastat in untreated adult men with Fabry disease shows how well it works and safety

  This study tests lucerastat to see if it can reduce Gb3 buildup and be safe in untreated adult men with Fabry disease.

  Recruiting Phase 3 Idorsia Pharmaceuticals Ltd. · Birmingham, Alabama and 15 other locations · NCT07778667

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Anderson-Fabry disease fitness improvement program

  This study tests whether a 12-week physiotherapy-led exercise program can improve function, fitness, strength, and quality of life in adults with Fabry disease.

  Recruiting General University Hospital, Prague · Prague · NCT07495410

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

• Quality of life for people 65+ with Fabry disease, treated or untreated

  This project will see if starting or continuing Fabry disease treatment changes quality of life over two and five years in people aged 65 and older.

  Recruiting Groupe Hospitalier Diaconesses Croix Saint-Simon · Paris, France · NCT07277361

• Agalsidase alfa for heart inflammation in Fabry disease measured by PET‑CMR

  This study will test whether agalsidase alfa reduces heart inflammation in people with Fabry disease by comparing PET‑CMR scans before and after 12 months of treatment.

  Recruiting Yonsei University · Seoul · NCT07235709

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.